Update on the Pharmacologic Treatment of Hypertension in Pediatrics

Journal of Clinical Hypertension

Volumn 14, Issue 6, 2012, Pages 383-387

  Blowey, Douglas L ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CANDESARTAN HEXETIL; ENALAPRIL; EPLERENONE; FELODIPINE; FOSINOPRIL; LISINOPRIL; LOSARTAN; METOPROLOL; OLMESARTAN; PLACEBO; TELMISARTAN; VALSARTAN;

ACUTE GASTROENTERITIS; ANTIHYPERTENSIVE THERAPY; COUGHING; CREATININE BLOOD LEVEL; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; HUMAN; HYPERTENSION; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHILD; CHILD WELFARE; HUMANS; HYPERTENSION; PEDIATRICS; TREATMENT OUTCOME; UNITED STATES;

EID: 84861874403     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2012.00659.x     Document Type: Review

References (29)

1. Flynn JT, Newburger JW, Daniels SR, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145:353-359
2. Li JS, Berezny K, Kilaru R, et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension. 2004;44:289-293.
3. Trachtman H, Hainer JW, Sugg J, et al. Efficacy, safety, and pharmacokinetics of candesartan cilexeti in hypertensive children aged 6 to 17years. J Clin Hypertens. 2008;10:743-750.
4. Flynn JT, Myers KEC, Neto JP, et al. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5years. Hypertension. 2008;52:222-228.
5. Soffer B, Zhang Z, Miller K, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. AJH. 2003;16:795-800.
6. Shahinfar S, Cano F, Soffer BA, et al. A double-blind, dose-response study of losartan in hypertensive children. AJH 2005;18:183-190.
7. Wells TG, Portman R, Norman P, et al. Safety, efficacy, and pharmacokinetics of telmisartan in pediatric patients with hypertension. Clin Pediatr. 2010;49: 938-946.
8. Wells T, Frame V, Soffer B, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42:870-880.
9. Hazan L, Hernández Rodriguez OA, Bhorat AE. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension. 2010;55:1323-1330.
10. Wells T, Blumer J, Meyers KEC, et al. Efficacy and safety of valsartan in children aged 6 to 16years with hypertension. J Clin Hypertens. 2011;13:357-365.
11. Sorof JM, Cargo P, Graepel J, et al. β-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol. 2002;17:345-350.
12. Li JS, Flynn JT, Portman R, et al. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr. 2010;157:282-287.
13. Batisky DL, Sorof JM, SUGG J, et al. Efficacy and safety of extended release metoprolol succinate and hypertensive children 6 to 16years of age: a clinical trial experience. J Pediatr. 2007;150:134-139.
14. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension. JAMA. 2008;300:924-932.
15. Trachtman H, Frank R, Mahan JD, et al. Clinical trial of extended-release felodipine and pediatric essential hypertension. Pediatr Nephrol. 2003;18:548-553.
16. Schaefer F, Van de Walle J, Zurowska A, et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6years of age. J Hypertens. 2010;28:1083-1090.
17. Simonetti GD, Rizzi M, Donadini R, et al. Effects of antihypertensive drugs on blood pressure and proteinuria in childhood. J Hypertens. 2007;25:2370-2376.
18. Li JS, Baker-Smith CM, Smith PB, et al. Racial difference in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis. Clin Pharmacol Ther. 2008;84:315-319.
19. Brewster IM, Van Montfara GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med. 2004;141:614-627.
20. The escape trial group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361:1639-50.
21. Wühl E, Mehls O, Schaefer F, The ESCAPE trial group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66:768-776.
22. Ellis D, Mortiz ML, Vats A, Janosky JE. Antihypertensive and renoprotective efficacy and safety of losartan: a long-term study in children with renal disorders. AJH. 2004;17:928-935.
23. Bloch MJ, Basile JN. Largest meta-analysis to date suggests that patients at risk for cardiovascular disease events derive benefit from antihypertensive therapy regardless of baseline blood pressure and to reduce vascular events, lowering blood pressure is more important than choice of antihypertensive drug class. J Clin Hypertens. 2009;11:743-745.
24. Śladowska-Kozlowska J, Litwin M, Niemirska A, et al. Change in left ventricular geometry during antihypertensive treatment in children with primary hypertension. Pediatr Nephrol. 2011;26:2201-2209.
25. Daniels SR, Loggie JM, Khoury P, et al. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with associated hypertension. Circulation. 1998;97:1907-1911
26. Sorof JM, Alexandrov AV, Garami Z, et al. Carotid ultrasonography for detection of vascular abnormalities in hypertensive children. Pediatr Nephrol. 2003;18:1020-1024.
27. Litwin M, Niemirska A, Śladowska-Kozlowska J, et al. Regression of target organ damage in children and adolescents with primary hypertension. Pediatr Nephrol. 2010;25:2489-2499.
28. Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl. 2005;23:S27-S33.
29. Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006;37:1933-1940